Skip to main content
Fig. 2 | Breast Cancer Research

Fig. 2

From: Plasma cell-free DNA (cfDNA) as a predictive and prognostic marker in patients with metastatic breast cancer

Fig. 2

ROC curve analysis to determinate the power of discrimination of the biomarkers between different patient response. Univariate approach for (A) CTC counts (AUC = 0.585; sensitivity = 47.6%; specificity = 63.3%), B cfDNA yield (AUC = 0.593; sensitivity = 59.8%; specificity = 46.7%), C CA15-3 levels (AUC = 0.491; sensitivity = 54.9%; specificity = 46.7%) and D AP levels (AUC = 0.573, sensitivity = 68.3%, specificity = 46.7%)

Back to article page